

24 November 2021

ASX Code: MXC

LSE Code: MXC

## Results of the 2021 Annual General Meeting

**MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company')** wishes to announce the results of voting on resolutions put to the Company's shareholders at its 2021 Annual General Meeting, held on 24 November 2021. This information is provided in accordance with Section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

The Company advises that all resolutions put to the meeting were decided on a poll, with the results of voting detailed in the accompanying table.

Resolution 2 of the Notice of Meeting was a "Spill Motion", which was required to be put to the meeting if 25% or more votes cast on Resolution 1, being a resolution to adopt the Company's Remuneration Report, were against the resolution. As the requisite threshold was not met, Resolution 2 (Spill Motion) was withdrawn during the course of the meeting.

--Ends--

**Authorised for release by the Executive Chairman, for further information please contact:**

**MGC Pharmaceuticals Ltd**

Roby Zomer  
CEO & Managing Director  
+61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

**UK Broker – Turner Pope**

Andy Thacker  
+44 203 657 0050  
[info@turnerpope.com](mailto:info@turnerpope.com)

**MGC Pharmaceuticals Ltd**

David Lim  
Company Secretary  
+61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

**UK PR Advisors – Tavistock**

Charles Vivian / Tim Pearson  
+44 207 920 3150  
[mgcpharma@tavistock.co.uk](mailto:mgcpharma@tavistock.co.uk)

### About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels



**MGC Pharmaceuticals Ltd**  
**ANNUAL GENERAL MEETING**  
**Wednesday, 24 November 2021**  
**Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	196,911,021 78.13%	50,900,206 20.20%	4,195,207 1.67%	84,284,921	201,106,228 79.80%	50,900,206 20.20%	84,284,921	Carried
2 Spill resolution	Ordinary	160,850,765 63.98%	86,364,924 34.35%	4,205,207 1.67%	84,870,459	WITHDRAWN			Withdrawn
3 Re-election of Director - Mr Nativ Segev	Ordinary	314,814,791 85.48%	49,235,093 13.37%	4,226,160 1.15%	4,475,869	319,040,951 86.63%	49,235,093 13.37%	4,475,869	Carried
4 Re-election of Director - Dr Ross Walker	Ordinary	317,317,287 86.54%	45,652,280 12.45%	3,703,197 1.01%	6,079,149	321,020,484 87.55%	45,652,280 12.45%	6,079,149	Carried
5 Ratify prior issue Shares- part consideration for the acquisition of MediCaNL	Ordinary	356,136,676 96.38%	9,014,956 2.44%	4,336,160 1.18%	3,264,121	360,472,836 97.56%	9,014,956 2.44%	3,264,121	Carried
6 Approval of issue deferred consideration Shares for Acquisition of MediCaNL	Ordinary	356,153,807 96.41%	8,968,710 2.43%	4,251,160 1.16%	3,378,236	360,404,967 97.57%	8,968,710 2.43%	3,378,236	Carried
7 Approval of 7.1A Mandate	Special	310,724,249 85.16%	48,427,643 13.27%	5,699,852 1.57%	7,900,169	316,424,101 86.73%	48,427,643 13.27%	7,900,169	Carried
8 Increase in total aggregate Remuneration for Non-Executive Directors	Ordinary	184,013,117 73.21%	62,990,279 25.07%	4,305,207 1.72%	121,443,310	188,318,324 74.94%	62,990,279 25.06%	121,443,310	Carried

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.